Abera Bioscience AB has received so-called Notice of Allowance of the company’s patent application “ Fusion polypeptides comprising one or more inclusion body tags, methods
The vaccine platform developed by Abera Bioscience AB (“Abera” or “the Company”) has been used in a collaboration between researchers at Johns Hopkins University School
Årsstämma 2021 i Abera Bioscience AB (”Abera” eller ”Bolaget”) hölls den 9 juni 2021. Mot bakgrund av COVID-19-pandemin genomfördes årsstämman enbart genom poströstning med stöd
I samband med Abera Bioscience årsstämma den 9 juni 2021 ges här en uppdatering av bolagets verksamhet. Istället för den planerade presentationen av VD, Maria
Abera Bioscience AB (publ) publicerar kvartalsrapport för Q1 2021. FINANSIELL ÖVERSIKT FÖRSTA KVARTALET 2021 Nettoomsättningen uppgick till 2 (306) TSEK. Resultatet efter finansiella poster uppgick
Abera Bioscience AB (publ) meddelar idag att bolaget publicerar årsredovisningen för 2020. Årsredovisning finns tillgänglig på bolagets hemsida www.aberabio.com/investors samt via PDF nedan. Läs rapporten
Aktieägarna i Abera Bioscience AB (publ), org. nr. 556909-0904, kallas härmed till årsstämma onsdagen den 9 juni 2021. Kallelse till årsmöte, samt formulär för
Abera Bioscience has received Notice of Allowance for the company’s patent application “Display of heterologous molecules on bacterial cells and membrane vesicles” from the US
Abera Bioscience AB (“Abera” or “the company”) is increasing its focus in oncology and has initiated preclinical studies at the contract research company Truly Labs.
Magnus Linderoth har förvärvat aktier i Abera Bioscience AB (”Abera” eller ”Bolaget”) och därmed passerat 5% ägande. Magnus Linderoth har meddelat bolaget att han kontrollerar
Idag, den 24 februari 2021, inleds handeln i Abera Bioscience AB:s (”Abera” eller ”Bolaget”) aktier på Spotlight Stock Market (”Spotlight”). Aktier handlas under kortnamnet ”ABERA”
Abera Bioscience AB (publ) publicerar bokslutskommuniké för 2020. Finansiell översikt över fjärde kvartalet och helåret 2020 FJÄRDE KVARTALET Övriga rörelseintäkter uppgick till 0 (1 041)
Abera Bioscience AB (”Abera” eller ”Bolaget”) har tidigare meddelat att bolagets bokslutskommuniké för perioden januari-december 2021 kommer att publiceras 26 februari 2020. Styrelsen i Abera
Den 2 februari 2021 avslutades teckningstiden i Abera Bioscience AB (”Abera” eller ”Bolaget”) nyemission om totalt cirka 24,1 MSEK inför notering på Spotlight Stock Market
Idag, den 19 januari 2021, inleds teckningstiden i Abera Bioscience AB:s (”Abera” eller ”Bolaget”) nyemission inför planerad notering på Spotlight Stock Market. Teckningstiden löper till
Abera Bioscience AB (”Abera” eller ”Bolaget”) meddelar härmed att Bolaget har godkänts för notering på Spotlight Stock Market. Godkännandet är villkorat erforderlig ägarspridning samt att
The two new board members bring decades of experience and expertise in drug development, manufacturing, clinical development and licensing from both biotech and big pharma
The decisions from the extra general meeting the 2th of December are now available on Abera Bioscience website through the minutes from the meeting. Full
The shareholders of Abera Bioscience AB, reg no 556909-0409, are hereby convened to the Extra General Meeting to be held the 2nd of December 2020
Abera appoints Maria Alriksson as new CEO for the company from mid-October 2020. She replaces Anders Ericson who has been CEO since 2015 in parallel
Abera gives a free research license for a vaccine collaboration with a reputable research organization in the US and a leading European University to develop
Abera and a non-disclosed party in Europe have initiated a collaboration to design and develop a vaccine candidate against Covid-19 based on Abera’s vaccine delivery
Abera and partners from The Netherlands, Germany, Switzerland, Denmark and Italy receive more than 2.5 MEUR of funding from the EU for the project Novel
Abera and Denmark-based collaborators Expres2ion Biotechnologies ApS and University of Copenhagen have received Eurostars funding for the project named OptiFemVac. Aim of the project is
Job opening: Research Technician position in Amsterdam Developing the next generation of vaccines and immunotherapeutics Abera Bioscience AB is a young biotech company that develops bacterial-based
Abera seeks an enthousiastic PhD student for participation in the EU funded ITN program VacPath that is aimed at developing novel vector-based vaccines against Chlamydia
From 10 to 14 June 2018, professor Joen Luirink, CSO of Abera, will attend the First international workshop on OMVs for vaccine development in Varadero,
Abera’s CSO, professor Joen Luirink, was invited to give a seminar at the annual Vaccine Symposium organized on 14 September 2017 by the Netherlands Organisation
Together with a multidisciplinary team of public and private partners spanning animal and human health, Abera announces the start of Bac Vactory on May 31,
Abera and Intravacc combine forces; first TKI funded project launched at Intravacc. The Dutch Life Sciences & Health (LSH) sector is one of nine
Abera has together with it’s collaborators received funding for the PNEUMONAV project. PNEUMONAV will develop a novel intranasal prototype vaccine against pneumococcal infections, which will
Get in contact with us via the contact form or email: info@aberabio.com
Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.